Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
about
Beta-blockers for hypertensionBeta-blockers for hypertensionCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trialsPopulation pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemateEffect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysisLipids, blood pressure and kidney update 2015Management of Patients Admitted with Acute Decompensated Heart FailureEuropean Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm SocietyEndpoints in stem cell trials in ischemic heart failureThird-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failureStage B: what is the evidence for treatment of asymptomatic left ventricular dysfunction?β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literatureNew advances in beta-blocker therapy in heart failureA Review of the External Validity of Clinical Trials with Beta-Blockers in Heart FailureEffect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trialsDrug therapy for prevention of recurrent myocardial infarctionManagement of acute coronary syndromesA critical evaluation of the NICE guidelines for post-myocardial infarction prophylaxis. National Institute for Clinical ExcellenceReverse Cardiac Remodeling: A Marker of Better Prognosis in Heart FailureBeta-blockers for hypertension.Office management of patients with diastolic heart failure.Individual patient data meta-analysis of beta-blockers in heart failure: rationale and designA review of carvedilol arrhythmia data in clinical trials.The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials.Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.Heart failure management: the present and the future.Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathyImpact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]).Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study)Effect of beta-blockers on the risk of atrial fibrillation in patients with acute myocardial infarction.β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.Management of chronic heart failure.Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalenceHeart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicineNovel treatment approaches in hypertensive type 2 diabetic patientsType of β-blocker use among patients with versus without diabetes after myocardial infarctionbeta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing.
P2860
Q24201511-F5CA8861-A8EE-4D7D-AC19-359789E01083Q24202812-147A4517-A296-44CC-968E-E0A4A5E2A940Q24614627-6A7163FA-A787-432A-9847-6E97E19154D3Q24647717-15B0F572-39E9-42CF-BC36-B908D926DB53Q26751460-650CEA7B-CF75-44EF-9B3D-D59A82628AC3Q26771550-F444A19A-F087-49AF-875D-BD2EFEF787B7Q26786085-03F39B18-CE70-4343-9032-D5BC37218415Q26796261-767EEF41-AF3E-45FD-81C3-823DC1B612EDQ26796330-2A71DD10-32F3-4EAC-9C82-170C897A993FQ26822825-C4A56AB2-2FCC-43ED-9D8A-53D44051136AQ26853063-5E25C5D6-ABA6-46AC-9209-DFD48572824AQ26861630-BEF1FCEF-62CD-4561-9101-FFCC2A668BEBQ26865919-234A2C33-84A5-4DAA-AA27-0C443237A91FQ28068618-CF3ED1C6-17B8-4F7B-A9A7-63A8369E22F6Q28087109-D9F760C6-F9F3-4D20-9E65-E3E360E377CEQ28165520-C34F8640-E849-4A0C-8120-9C96FCEC19D0Q28189763-940B369F-2171-469F-B2D3-67F08E776494Q28192295-F3153496-7603-4792-8B56-A0872992EBD1Q28264330-188ADCB1-139C-476A-A459-1EEFA4470344Q30238911-42846D3F-45D5-46DD-BB7C-74F0BA071012Q30486094-DC74835C-0085-4C6A-9033-0FF955BC0A6BQ30534526-F1E7F874-C3B3-43D0-B4D4-8FB7323955AFQ30992419-90A1F7D9-EA26-4D7A-8E8B-3099A039C474Q31150630-8F9C4303-E35B-429D-B9FD-FE40A3749A07Q33240910-14178B1A-C18F-4A85-A270-C575FAF9DA6FQ33561456-3B6CE824-C719-42C9-8A42-015268E4A8F7Q33595716-722D14AB-3BB0-4BB7-BBBA-85AE4DFAEEE0Q33605156-83F9D3CF-EA01-4165-B287-568C80AFBF90Q33606538-D46244A1-1077-41A7-A036-5F7E90554E80Q33647497-7AAE5F9D-B5C7-4AE6-893A-9306B0E1575AQ33675490-133AA8B2-ACB1-45CD-BB92-5D00CAEB144BQ33682749-F170335F-9A66-4413-B174-2DEFAFC9783CQ33754067-8A9ABCAC-8D13-49A3-8C4B-5EAECD9B9566Q33758547-87B5A377-439F-4802-96F9-6056A073C3FAQ33811699-55723D58-54D8-4216-836E-6856EEC43459Q33902595-A5F4F37F-0130-4C38-B374-168070277749Q33902610-452A8BF5-8BC4-4415-9B23-929922211967Q34023579-19A36A79-9BBE-4C8E-AE09-D8DA774A4116Q34117758-6105DC4A-F728-47D0-8FA3-8A454934E686Q34125706-8744563C-614E-4C53-A304-49090A6FDBF6
P2860
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Effect of carvedilol on outcom ...... he CAPRICORN randomised trial.
@en
Effect of carvedilol on outcom ...... he CAPRICORN randomised trial.
@nl
type
label
Effect of carvedilol on outcom ...... he CAPRICORN randomised trial.
@en
Effect of carvedilol on outcom ...... he CAPRICORN randomised trial.
@nl
prefLabel
Effect of carvedilol on outcom ...... he CAPRICORN randomised trial.
@en
Effect of carvedilol on outcom ...... he CAPRICORN randomised trial.
@nl
P1433
P1476
Effect of carvedilol on outcom ...... he CAPRICORN randomised trial.
@en
P2093
H J Dargie
P304
P356
10.1016/S0140-6736(00)04560-8
P407
P577
2001-05-01T00:00:00Z